Status:
UNKNOWN
Colonization of Skin by M. Luteus Q24 Probiotic
Lead Sponsor:
BLIS Technologies Limited
Conditions:
Microbial Colonization
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the skin quality improvement and colonization efficacy following the application of probiotic Micrococcus luteus Q24 (BLIS Q24) to the face from a serum format...
Detailed Description
This is a randomized double-blind baseline controlled pilot study with no crossover for the assessment of any changes to the microbial make-up of the skin (The local skin microbiome), detection of col...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- In general good health 18 - 80 years of age.
- Practice good general body hygiene.
- Exclusion criteria:
- Have a history of autoimmune disease or are immunocompromised (have a weakened immune system).
- Are on concurrent antibiotic therapy or regular antibiotic use within the last 1 week.
- People with allergies or sensitivity to dairy.
- People with an open wound on the Blis Q24 application sites.
Exclusion
Key Trial Info
Start Date :
October 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06137209
Start Date
October 2 2023
End Date
March 15 2024
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blis Technologies Ltd
Dunedin, Otago, New Zealand, 9012